Prevention of non-A, non-B, post-transfusion hepatitis with intravenous administration of human immune serum globulin (Venoglobulin-I).

概要

論文の詳細を見る
Ninety-six patients admitted in the departments of gynecology and urology were enrolled in this study. They were devided into either group to be infused intravenous intact immunoglobulin (Venoglobulin-I, V-I) or not, as alternatively as possible. 9 (22.5%) out of 40 patients (V-I group) who received each vial containing 2.5g of V-I just before and after blood transfusions and 15 (26.8%) out of 56 patients who did not (control group) developed non-A, non-B post-transfusion hepatitis (PTH).<BR>In the patients transfused less than 1, 800ml, 5 patients (15.2%) in V-I group and 10 (23.3%) in control group developed PTH.<BR>There was no differrence of the incubation period, the highest level of GPT and the progression rates to chronic liver diseases in the patients with PTH in both group.<BR>No PTH type B developed.<BR>In conclusion no evidence of any clinical effectiveness of V-I infusion was found.
社団法人日本肝臓学会の論文